|
CN106715430A
|
|
Inhibiting the transient receptor potential A1 ion channel
|
|
EP3180342A1
|
|
Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
|
|
EP3180337A1
|
|
Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
|
WO2016023832A1
|
|
Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
|
|
WO2016023826A1
|
|
Quinazoline-2,4(1h,3h)-dione derivatives as trcp5 modulators for the treatment of neuropsychiatry disorders
|
|
WO2016023830A1
|
|
Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
|
|
US2016009708A1
|
|
Compounds useful for treating disorders related to TRPA1
|
|
RS56066B1
|
|
Substituted xanthines and methods of use thereof
|
|
TW201444844A
|
|
Substituted xanthines and methods of use thereof
|
|
AU2013204105A1
|
|
Compounds for modulating TRPV3 function
|
|
AU2012244254A1
|
|
Compounds for modulating TRPV3 function
|
|
TW201311690A
|
|
Inhibiting transient receptor potential ion channel TRPA1
|
|
WO2012050641A2
|
|
Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
|
|
WO2010138879A1
|
|
Compounds useful for treating disorders related to trpa1
|
|
WO2010132838A1
|
|
Compounds useful for treating disorders related to trpa1
|
|
TW201026700A
|
|
Compositions useful for treating disorders related to TRPA1
|
|
WO2010036821A1
|
|
Methods and compositions for treating respiratory disorders
|
|
WO2010017368A2
|
|
Methods and compositions for treating anxiety
|
|
WO2009158719A2
|
|
Methods and compositions for treating disorders
|
|
WO2009140519A1
|
|
Compounds and compositions for treating chemical warfare agent-induced injuries
|
